Key facts
- It has raised $71.7M across 7 recorded rounds; the latest was Early Stage VC ($33.5M) in Aug 2018.
- Notable investors include National Institutes of Health, Edge (Onalaska), Lung, NIH Office of the Director, National Cancer Institute — 14 tracked in total.
- Recombinetics has filed 13 Form Ds with the SEC since 2013, most recently Feb 2019 ($7.7M sold to 11 investors).
- Status: Privately Held (backing).
Investors
14+- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Recombinetics
Funding rounds
7 roundsAbout Recombinetics
Developer of gene editing technologies designed to improve human health through advanced disease models and regenerative medicine. The company's technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools, enabling biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.
- Sector
- Healthcare
- HQ
- Eagan, MN, United States
- Founded
- 2008
- Employees
- 21
- Website
- recombinetics.com/
- Ownership
- Privately Held (backing)
Recombinetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Recombinetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Recombinetics in its N-PORT filings yet. We sweep new filings monthly.